GT BIOPHARMA, INC. Derivative Liability, Fair Value, Gross Liability
GT BIOPHARMA, INC. (GTBP) had Derivative Liability, Fair Value, Gross Liability of $30.00 thousand as of 2021-12-31, per its 10-K filed 2023-03-30.
Discontinued › Notes
us-gaap:DerivativeFairValueOfDerivativeLiability · last filed 2023-03-30
- 2021-12-31: Derivative Liability, Fair Value, Gross Liability $30.00K.
| Period end | Derivative Liability, Fair Value, Gross Liability |
|---|---|
| 2021-12-31 | $30.00K 10-K · filed 2023-03-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |